🇺🇸 E2020 in United States

23 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Atrial Fibrillation — 3 reports (13.04%)
  2. Syncope — 3 reports (13.04%)
  3. Vomiting — 3 reports (13.04%)
  4. Abdominal Pain — 2 reports (8.7%)
  5. Bundle Branch Block Left — 2 reports (8.7%)
  6. Cardiac Failure Congestive — 2 reports (8.7%)
  7. Convulsion — 2 reports (8.7%)
  8. Fall — 2 reports (8.7%)
  9. Pneumonia — 2 reports (8.7%)
  10. Sepsis — 2 reports (8.7%)

Source database →

E2020 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is E2020 approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for E2020 in United States?

Eisai Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.